Bio Monthly (June 2026): OpenLabs Launch, DeSci Berlin, PeptAI's First Wet-Lab Results
Highlights from June in the Biosphere 🌐For a hundred years, getting cured meant waiting on an institution. Now the patient is the principal investigator. A founder built a cancer vaccine for his dog. A woman self-treated her breast cancer. A whole generation is tracking and dosing without asking permission. The dem...
For a hundred years, getting cured meant waiting on an institution. Now the patient is the principal investigator. A founder built a cancer vaccine for his dog. A woman self-treated her breast cancer. A whole generation is tracking and dosing without asking permission. The demand for self-directed science is already mainstream. What's missing is open infrastructure to do it safely, at scale.
That's what Bio is building. Today's system spends ~$2.6B and 10–15 years per drug, with 96% of trials failing, and most of that cost is bureaucracy, not discovery. Our goal is to treat the code of life as a public good: cures anyone can fund, own, build on, and verify in the open.
This month at a glance:
PeptAI's first wet-lab results - AI-designed VEGFR2 binders, validated by SPR.
DeSci Berlin 2026 - ~20 talks on scientific singularity and agentic science.
BIOS designed a drug candidate in under an hour, for under $7.
veBIO retroactive staking rewards live across five projects.
$1M seed for ARTAN Bio, led by VitaRNA.
PeptAI: First Wet-Lab Results Against VEGFR2
PeptAI returned its first wet-lab results. Its AI agents designed protein binders from scratch against VEGFR2, a cancer target, and those designs were tested in the lab using SPR (surface plasmon resonance, a method that measures how strongly and how quickly a molecule binds to its target). The data is now feeding the next round of designs, showing the agents which regions worked and which to drop, a closed loop where each physical result sharpens the next generation.
Newsletter
Get the latest updates from the Bio ecosystem
New launches, research progress, and ways to get involved across the Biosphere.
What is OpenLabs?
OpenLabs is the coordination and collaboration layer where humans and AI agents turn scientific ideas into funded execution. Scientists post ideas, communities form around the ones worth pursuing, agents draft votes and summarize progress, bounties fund the work, and projects graduate to the launchpad.
DeSci Berlin 2026: Scientific Singularity and Agentic Science
In June 2026, Bio hosted the fifth edition of DeSci Berlin during Berlin Blockchain Week, two days and around twenty talks, with speakers from Bio Protocol, Molecule, Foresight Institute, VitaDAO, and more.
One shift kept surfacing: science is starting to behave like software, fundable, ownable, composable, and now operable by agents. Bio founder Paul Kohlhaas opened by reframing a familiar number: it costs about $2.5 billion to bring a drug to market, and that's not the cost of discovery — it's the cost of the bureaucracy around it.
Three threads ran across the two days. The loop is starting to close — an AI designs a molecule, a lab tests it, the result trains the next design; BIOS generated binders for about $10 a verified candidate, and PeptAI ran the same loop on real peptide targets. Funding is catching up to the science, tokenized IP, a compliant path from community to cap table, and OpenLabs routing staking yield into research. The patient is becoming the principal investigator. consumer products and owned, encrypted data are becoming the way into real research.
BIOS AI Scientist: A Drug Candidate in Under an Hour, for Under $7
BIOS, Bio's AI scientist, shipped a pipeline that takes a protein target to ranked therapeutic candidates in under an hour. Three AI engines (RFdiffusion3, BoltzGen, and PXDesign) run in parallel on every campaign, predicting thousands of candidates per run; a dedicated pipeline then filters them across six gates — structural, agreement, physics, selectivity, dynamics, and developability, down to the most likely to bind. Top candidates go to a robotic wet-lab system that synthesizes and tests them, then sends the results back to the models.
Also new in BIOS this month:
Image segmentation: upload an image, click an example object, and BIOS finds and counts similar structures across it — microscopy-style analysis inside the chat, no separate tool needed.
Object tracking: upload an MP4, click an object in the first frame, and BIOS follows it across the video — useful for tracking cells, particles, or moving subjects in short scientific clips.
As part of Bio Season 2, veBIO stakers receive automatic token distributions (airdrops) from every new project that launches on the network — passive yield as the network expands. The vision: stakers wake up to an array of new DeSci tokens sent to their wallet. In June 2026, ecosystem rewards went live across five projects: FOXO3, Holi, GALE, RELIEVA, and AUBRAI.
ARTAN Bio closed a $1M seed round led by Michael Torres of VitaRNA. ARTAN's lead platform is built around an engineered suppressor tRNA system that restores protein translation in cells carrying disease-causing nonsense mutations. The round funds the move from preclinical research toward first-in-human development, including IND-enabling studies, manufacturing scale-up, and regulatory prep.
AthenaDAO joined the Menopause Today Special to discuss Dr. Mario Cordero's newly published paper on ovarian aging, fertility-extending drugs, and AI-driven drug discovery, and seeded a menopause drug-discovery program at Gero.
HairDAO was featured by Compound VC for its new telehealth products, including a slow-release minoxidil drug.
Quantum Biology DAO launched an educational series on quantum biology (first class July 9, led by Alessandro Lodesani, COO of the Quantum Biology Institute) and hosted an interview with Dr. Nathan Babcock.
SpineDAO published a piece on Lamina, a clinician-led, AI-powered triage companion for spine-care patients.
ValleyDAO released its $HEMPY Research Update: 20+ enzyme formulations tested, softer hemp fibers via biotech, and PFAS-free water repellency.
Bio Media & Events (June 2026)
PeptAI X Space: Bio hosted a conversation on where AI agent-driven drug discovery and peptide science are heading. Listen to the recording.
What was announced at DeSci Berlin 2026?DeSci Berlin 2026, the fifth edition, focused on scientific singularity and agentic science across ~20 talks. Key themes: the AI design-test-learn loop is closing (BIOS generated binders at ~$10 per verified candidate), tokenized IP is creating a compliant path from community to cap table, and patients are becoming principal investigators.
What is OpenLabs?OpenLabs is Bio Protocol's coordination layer where humans and AI agents turn scientific ideas into funded projects — from a public idea to community formation, agent-drafted votes, bounties, and a launchpad path.
What were PeptAI's first wet-lab results?In June 2026, PeptAI's AI agents designed protein binders from scratch against VEGFR2, a cancer target. The designs were validated in the lab by SPR, and the results now feed the next design cycle.
